HBP:CC - Helix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(TheNewswire)
Toronto, Ontario - TheNewswire - October 10, 2023 - Helix BioPharma Corp. (TSX:HBP) (“ Helix ” or the“ Company ”), an immune-oncology antibody-drug-conjugate companydeveloping an innovative drug platform for the treatment of cancer,announced today that the Company will present new preclinical data onL-DOS47 in combination with PD1 checkpoint inhibition at the 2023AACR-NCI-EORTC International Conference on Molecular Targets andCancer Therapeutics in the Hynes Convention Center, Boston, via inperson attendance, October 11-15, 2023.
Poster Presentation Details:
Title: Neutralizing Acidosis with ADC L-DOS47 UreaseImmunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in APreclinical Orthotopic Model of Pancreatic Adenocarcinoma
Abstract Number: 35494
Poster Presentation Date and Time: Friday, October 13,12:30 pm – 4:00 pm
Location: Level 2, Exhibit Hall D
Poster Session B, Poster Number:B125
During the conference, Helix will highlight theenhanced effects of anti-PD1 immunotherapy when combined with L-DOS47in an orthotopic Pancreatic tumor model in mice. The drug has alreadybeen administered to over 120 patients in the clinic across 4 clinicaltrials and has been shown to be safe and welltolerated. Additionally, L-DOS47 has also demonstrated promisinganti-tumor activity across a range of doses, both as monotherapy andin combination with chemotherapy agents . TheCompany is open to collaborating with the right partner(s) to explorepotential synergies with anti-PD1 and other treatment regimens.
“We are enthusiastic about the results of thesestudies, which showcase a distinctive ADC platform. This platform hasthe capability to synergize effectively with a wide range ofapproaches, such as chemotherapy, radiation therapy, immunotherapy,and emerging cell therapies. This synergy aims to boost effectivenesswhile minimizing safety issues.” said Jacek Antas, Helix’s ChiefExecutive Officer.
More details about the AACR-NCI-EORTC Conference areavailable on the official website . Full text of the abstracts is now available on theirwebsite.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a clinical-stagebiopharmaceutical company developing unique therapies in the field ofimmune-oncology for the prevention and treatment of cancer based onour proprietary technological platform DOS47. Helix is listed on theTSX under the symbol “HBP”.
About DOS47
DOS47 is based upon a naturally occurring enzymeisolated from the jack-bean plant called urease that breaks down anatural substance found in the body, urea, into metabolites thatinclude ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, the Companybelieves DOS47 can modify the microenvironmental condition surroundingcancerous cells in a manner that leads to cancer cell death. DOS47increases the pH of the tumor microenvironment, effectively reversingthe acidic extracellular conditions that are believed to promotepersistence of tumor cells and disable immune cells. Raising the pH ofthe tumor microenvironment helps to reactivate immune cells enhancingtheir ability to kill cancer. DOS47 is a platform with which tobuild targeted antibody-drug conjugates.
About L-DOS47
L-DOS47 is Helix's first targeted antibody-drugconjugate that uses an anti-CEACAM6 camelid antibody to localize toCEACAM6-expressing tumors. Its design is an innovative approach toneutralize the acidic pH in the tumor microenvironment surroundingcancer cells in a manner that leads to their destruction.
For more information, please contact:
Helix BioPharma Corp.
Suite 2704, 401 Bay Street
Toronto, Ontario, M5H 2Y4
Tel: 905-841-2300
Namrata Malhotra, Corporate Secretary namrata@grovecorp.ca
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statementsand information (collectively, “forward-looking statements”)within the meaning of applicable Canadian securities laws.Forward-looking statements are statements and information that are nothistorical facts but instead include financial projections andestimates, statements regarding plans, goals, objectives, intentions,and expectations with respect to the Company’s future business,operations, research, and development, including the Company’sactivities relating to DOS47. Forward-looking statements can furtherbe identified by the use of forward-looking terminology such as“ongoing”, “estimates”, “expects”, or the negative thereofor any other variations thereon or comparable terminology referring tofuture events or results, or that events or conditions “will”,“may”, “could”, or “should” occur or be achieved, orcomparable terminology referring to future events or results.
Forward-looking statements are statements about thefuture and are inherently uncertain and are necessarily based upon anumber of estimates and assumptions that are also uncertain. Althoughthe Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks anduncertainties, and undue reliance should not be placed on suchstatements. Forward-looking statements, including financial outlooks,are intended to provide information about management’s current plansand expectations regarding future operations, including withoutlimitation, future financing requirements, and may not be appropriatefor other purposes. Certain material factors, estimates or assumptionshave been applied in making forward-looking statements in this newsrelease.
The Company’s actual results could differ materiallyfrom those anticipated in the forward-looking statements contained inthis news release as a result of numerous known and unknown risks anduncertainties, including without limitation; the risk that theCompany’s assumptions may prove to be incorrect; the risk thatadditional financing may not be obtainable in a timely manner, or atall, and that clinical trials may not commence or complete withinanticipated timelines or the anticipated budget or may fail; thirdparty suppliers of necessary services or of drug product and othermaterials may fail to perform or be unwilling or unable to supply theCompany, which could cause delay or cancellation of the Company’sresearch and development activities; necessary regulatory approvalsmay not be granted or may be withdrawn; the Company may not be able tosecure necessary strategic partner support; general economicconditions, intellectual property and insurance risks; changes inbusiness strategy or plans; and other risks and uncertainties referredto elsewhere in this news release, any of which could cause actualresults to vary materially from current results or the Company’santicipated future results. Certain of these risks and uncertainties,and others affecting the Company, are more fully described in theCompany’s annual management’s discussion and analysis for the yearended July 31, 2022, under the heading “Risks and Uncertainties”and Helix’s Annual Information Form, in particular under theheadings “Forward-looking Statements” and “Risk Factors”, andother reports filed under the Company’s profile on SEDAR atwww.sedar.com from time to time. Forward-looking statements andinformation are based on the beliefs, assumptions, opinions, andexpectations of Helix’s management on the date of this new release,and the Company does not assume any obligation to update anyforward-looking statement or information should those beliefs,assumptions, opinions or expectations, or other circumstances change,except as required.
Copyright (c) 2023 TheNewswire - All rights reserved.